Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZK 245186 · 2 trials · 1 indication
Eczema area and severity index
Ezcema area and severity index
| Arm | Type | Description |
|---|---|---|
| 0.01% ointment | ACTIVE_COMPARATOR | Lowest concentration |
| 0.03% ointment | ACTIVE_COMPARATOR | Middle concentration |
| 0.1% ointment | ACTIVE_COMPARATOR | Highest concentration |
| Placebo (vehicle without active) | PLACEBO_COMPARATOR | No active ingredient |
| Zk 245186 0.01% ointment | ACTIVE_COMPARATOR | Active treatment, lowest dose |
| ZK 245186 0.03% ointment | ACTIVE_COMPARATOR | Active comparator middle dose |
| ZK 245186 0.1% ointment | ACTIVE_COMPARATOR | Active comparator highest dose |
| Vehicle ointment | PLACEBO_COMPARATOR | Placebo comparator |
| Name | Type | Description |
|---|---|---|
| ZK245186 | DRUG | Daily topical application |
| Placebo (vehicle without active ingredient) | DRUG | Daily topical application |
| ZK 245186 | DRUG | Once daily topical non-occlusive application for up to 4 weeks |
| Placebo (vehicle ointment) | DRUG | Once daily topical non-occlusive application for up to 4 weeks |
Inclusion Criteria: * Diagnosis of atopic dermatitis according to Hanifin and Rajka criteria * Body surface area affected by atopic dermatitis at or less than 15% at start of treatment Exclusion Criteria: * Pregnancy and breast-feeding * Conditions that may pose a threat to the patient or effect ...
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
ZK 245186 is an investigational small molecule being developed for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The drug is being studied for its efficacy and safety in adult patients with this condition.
ZK 245186 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer is conducting clinical trials to evaluate the drug's safety and efficacy in treating atopic dermatitis. The company's stock is traded under the ticker symbol BAYRY on the over-the-counter market.
ZK 245186 is currently in Phase 2 clinical development. It has completed two Phase 2 trials, with a total of 327 participants enrolled. The drug is still investigational and has not received FDA approval. Further studies would be needed to establish its safety and efficacy before any regulatory submission.
ZK 245186 has been evaluated in two completed Phase 2 clinical trials. The first, NCT00944632, enrolled 64 participants in South Africa and studied dose escalation of different concentrations. The second, NCT01228513, enrolled 263 participants in the United States and Japan to assess efficacy and safety of various concentrations.
ZK 245186 is a small molecule developed for topical application in atopic dermatitis. Its specific molecular target has not been disclosed in available information. The drug is being studied for its ability to treat the condition, but the precise mechanism of action is not publicly detailed.